Work

Glucagon-like peptide-1 receptor agonists for obesity: Growing popularity met with growing questions over safety

Year: 2026

Type: article

Abstract: Glucagon-like peptide-1 (GLP-1)-based medications, such as semaglutide and tirzepatide, have transformed obesity care. However, rising use brings concerns about side effects, long-term outcomes, and unregulated products. Ensuring safe access requires oversight, monitoring, and coordinated clinical care.

Source: PLoS Medicine

DOI: 10.1371/journal.pmed.1004871

Authors: Ariana M. Chao, Adam Gilden, Thomas A. Wadden

Institutions: Johns Hopkins University, Johns Hopkins Medicine, University of Colorado Anschutz, University of Colorado Denver, University of Pennsylvania

Language: English

Topic: Pharmacology and Obesity Treatment

Subfield: Pharmacology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $6,460